Adequate and well-controlled studies. 21 CFR §314.126 (2020).

• PubMed
Adequate and well-controlled studies. 21 CFR §314.126 (2020).)| false
• Export Citation

Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 tears of US Food and Drug Administration approvals. JAMA Intern Med 2015;175:1992–1994.

• PubMed
Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 tears of US Food and Drug Administration approvals. JAMA Intern Med 2015;175:1992–1994.)| false
• Search Google Scholar
• Export Citation

Zettler M, Basch E, Nabhan C. Surrogate end points and patient-reported outcomes for novel oncology drugs approved between 2011 and 2017. JAMA Oncol 2019;5:1358–1359.

• PubMed
Zettler M, Basch E, Nabhan C. Surrogate end points and patient-reported outcomes for novel oncology drugs approved between 2011 and 2017. JAMA Oncol 2019;5:1358–1359.)| false
• Search Google Scholar
• Export Citation

Tibau A, Molto C, Borrell M, et al. Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration based on single-arm trials. JAMA Oncol 2018;4:1610–1611.

• PubMed
Tibau A, Molto C, Borrell M, Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration based on single-arm trials. JAMA Oncol 2018;4:1610–1611.)| false
• Search Google Scholar
• Export Citation

Shepshelovich D, Tibau A, Goldvaser H, et al. Postmarketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials. J Clin Oncol 2018;36:1798–1804.

• PubMed
Shepshelovich D, Tibau A, Goldvaser H, Postmarketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials. J Clin Oncol 2018;36:1798–1804.)| false
• Search Google Scholar
• Export Citation

Prasad V, Kim C, Burotto M, et al. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med 2015;175:1389–1398.

• PubMed
Prasad V, Kim C, Burotto M, The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med 2015;175:1389–1398.)| false
• Search Google Scholar
• Export Citation

Kovic B, Jin X, Kennedy SA, et al. Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis. JAMA Intern Med 2018;178:1586–1596.

• PubMed
Kovic B, Jin X, Kennedy SA, Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis. JAMA Intern Med 2018;178:1586–1596.)| false
• Search Google Scholar
• Export Citation

Hwang TJ, Gyawali B. Association between progression-free survival and patients’ quality of life in cancer clinical trials. Int J Cancer 2019;144:1746–1751.

• PubMed
Hwang TJ, Gyawali B. Association between progression-free survival and patients’ quality of life in cancer clinical trials. Int J Cancer 2019;144:1746–1751.)| false
• Search Google Scholar
• Export Citation

Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ 2017;359:j4530.

• PubMed
Davis C, Naci H, Gurpinar E, Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ 2017;359:j4530.)| false
• Search Google Scholar
• Export Citation

Del Paggio JC, Sullivan R, Schrag D, et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol 2017;18:887–894.

• PubMed
Del Paggio JC, Sullivan R, Schrag D, Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol 2017;18:887–894.)| false
• Search Google Scholar
• Export Citation

Vokinger KN, Hwang TJ, Grischott T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol 2020;21:664–670.

• PubMed
Vokinger KN, Hwang TJ, Grischott T, Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol 2020;21:664–670.)| false
• Search Google Scholar
• Export Citation

Booth CM, Del Paggio JC. Approvals in 2016: questioning the clinical benefit of anticancer therapies. Nat Rev Clin Oncol 2017;14:135–136.

• PubMed
Booth CM, Del Paggio JC. Approvals in 2016: questioning the clinical benefit of anticancer therapies. Nat Rev Clin Oncol 2017;14:135–136.)| false
• Search Google Scholar
• Export Citation

Tibau A, Molto C, Ocana A, et al. Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration. J Natl Cancer Inst 2018;110:486–492.

• PubMed
Tibau A, Molto C, Ocana A, Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration. J Natl Cancer Inst 2018;110:486–492.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. New molecular entity (NME) drug and new biologic approvals. Accessed July 20, 2021. Available at: https://www.fda.gov/drugs/nda-and-bla-approvals/new-molecular-entity-nme-drug-and-new-biologic-approvals

• PubMed
U.S. Food & Drug Administration. New molecular entity (NME) drug and new biologic approvals. Accessed July 20, 2021. Available at: https://www.fda.gov/drugs/nda-and-bla-approvals/new-molecular-entity-nme-drug-and-new-biologic-approvals)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Efficacy supplement approvals. Accessed July 20, 2021. Available at: https://www.fda.gov/drugs/nda-and-bla-approvals/efficacy-supplement-approvals

• PubMed
U.S. Food & Drug Administration. Efficacy supplement approvals. Accessed July 20, 2021. Available at: https://www.fda.gov/drugs/nda-and-bla-approvals/efficacy-supplement-approvals)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. CDER breakthrough therapy designation approvals. Accessed July 20, 2021. Available at: https://www.fda.gov/media/95302/download

• PubMed
U.S. Food & Drug Administration. CDER breakthrough therapy designation approvals. Accessed July 20, 2021. Available at: https://www.fda.gov/media/95302/download)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Search orphan drug designations and approvals. Accessed July 20, 2021. Available at: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm

• PubMed
U.S. Food & Drug Administration. Search orphan drug designations and approvals. Accessed July 20, 2021. Available at: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Accelerated approvals. Accessed July 20, 2021. Available at: https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/nda-and-bla-approvals

• PubMed
U.S. Food & Drug Administration. Accelerated approvals. Accessed July 20, 2021. Available at: https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/nda-and-bla-approvals)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Accessed July 21, 2021. Available at: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools

• PubMed
U.S. Food & Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Accessed July 21, 2021. Available at: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools)| false
• Search Google Scholar
• Export Citation

Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol 2016;34:2925–2934.

• PubMed
Schnipper LE, Davidson NE, Wollins DS, Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol 2016;34:2925–2934.)| false
• Search Google Scholar
• Export Citation

Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 2017;28:2340–2366.

• PubMed
Cherny NI, Dafni U, Bogaerts J, ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 2017;28:2340–2366.)| false
• Search Google Scholar
• Export Citation

Cherny NI, de Vries EGE, Dafni U, et al. Comparative assessment of clinical benefit using the ESMO-Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework net health benefit score. J Clin Oncol 2019;37:336–349.

• PubMed
Cherny NI, de Vries EGE, Dafni U, Comparative assessment of clinical benefit using the ESMO-Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework net health benefit score. J Clin Oncol 2019;37:336–349.)| false
• Search Google Scholar
• Export Citation

Ben-Aharon O, Magnezi R, Leshno M, et al. Association of immunotherapy with durable survival as defined by value frameworks for cancer care. JAMA Oncol 2018;4:326–332.

• PubMed
Ben-Aharon O, Magnezi R, Leshno M, Association of immunotherapy with durable survival as defined by value frameworks for cancer care. JAMA Oncol 2018;4:326–332.)| false
• Search Google Scholar
• Export Citation

Roydhouse JK, King-Kallimanis BL, Howie LJ, et al. Blinding and patient-reported outcome completion rates in US Food and Drug Administration cancer trial submissions, 2007-2017. J Natl Cancer Inst 2019;111:459–464.

• PubMed
Roydhouse JK, King-Kallimanis BL, Howie LJ, Blinding and patient-reported outcome completion rates in US Food and Drug Administration cancer trial submissions, 2007-2017. J Natl Cancer Inst 2019;111:459–464.)| false
• Search Google Scholar
• Export Citation

Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol 2018;15:183–192.

• PubMed
Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol 2018;15:183–192.)| false
• Search Google Scholar
• Export Citation

Zettler M, Nabhan C. Fulfillment of postmarketing requirements to the FDA for therapies granted oncology indications between 2011 and 2016. JAMA Oncol 2018;4:993–994.

• PubMed
Zettler M, Nabhan C. Fulfillment of postmarketing requirements to the FDA for therapies granted oncology indications between 2011 and 2016. JAMA Oncol 2018;4:993–994.)| false
• Search Google Scholar
• Export Citation

Basch E. Toward patient-centered drug development in oncology. N Engl J Med 2013;369:397–400.

• PubMed
Basch E. Toward patient-centered drug development in oncology. N Engl J Med 2013;369:397–400.)| false
• Search Google Scholar
• Export Citation

Allegra CJ, Goodwin PJ, Ganz PA. Can we find the positive in negative clinical trials? J Natl Cancer Inst 2019;111:637–638.

• PubMed
Allegra CJ, Goodwin PJ, Ganz PA. Can we find the positive in negative clinical trials? J Natl Cancer Inst 2019;111:637–638.)| false
• Search Google Scholar
• Export Citation

Nass SJ, Rothenberg ML, Pentz R, et al. Accelerating anticancer drug development—opportunities and trade-offs. Nat Rev Clin Oncol 2018;15:777–786.

• PubMed
Nass SJ, Rothenberg ML, Pentz R, Accelerating anticancer drug development—opportunities and trade-offs. Nat Rev Clin Oncol 2018;15:777–786.)| false
• Search Google Scholar
• Export Citation

Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med 2019;179:906–913.

• PubMed
Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med 2019;179:906–913.)| false
• Search Google Scholar
• Export Citation